Tipiracil is a drug used in the treatment of cancer. It is approved for use as part of the combination drug trifluridine/tipiracil (brand name Lonsurf) for the treatment of unresectable advanced or recurrent colorectal cancer. Tipiracil works by inhibiting thymidine phosphorylase, which helps maintain the levels of trifluridine, allowing it to incorporate into cancer cell DNA more effectively and inhibit cancer cell growth.
Parent: Tipiracil
Parent: Tipiracil
Impurities in Tipiracil can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Tipiracil is used in combination with trifluridine to treat unresectable advanced or recurrent colorectal cancer. It helps enhance the effectiveness of trifluridine by preventing its breakdown, thereby allowing the drug to inhibit cancer cell proliferation more effectively.
Tipiracil belongs to the class of thymidine phosphorylase inhibitors. It is used as part of a combination therapy to enhance the efficacy of nucleoside analogs like trifluridine in cancer treatment.
Common adverse effects include neutropenia, anemia, fatigue, nausea, vomiting, diarrhea, and loss of appetite. Regular blood count monitoring is recommended due to the risk of severe neutropenia.
Clinical trials have demonstrated that the combination of trifluridine and tipiracil can prolong overall survival and progression-free survival in patients with advanced colorectal cancer who have previously been treated with other therapies. However, its effectiveness varies based on individual patient factors.
